2005
Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction
Solomon SD, Skali H, Anavekar NS, Bourgoun M, Barvik S, Ghali JK, Warnica JW, Khrakovskaya M, Arnold JM, Schwartz Y, Velazquez EJ, Califf RM, McMurray JV, Pfeffer MA. Changes in Ventricular Size and Function in Patients Treated With Valsartan, Captopril, or Both After Myocardial Infarction. Circulation 2005, 111: 3411-3419. PMID: 15967846, DOI: 10.1161/circulationaha.104.508093.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug Therapy, CombinationElectrocardiographyFemaleHeart VentriclesHospitalizationHumansHypertrophy, Left VentricularMaleMiddle AgedMyocardial InfarctionPrognosisStroke VolumeTetrazolesTreatment OutcomeValineValsartanVentricular Dysfunction, LeftConceptsAngiotensin receptor blockersMyocardial infarctionEjection fractionEchocardiographic measuresPo bidPo tidHeart failureTreatment armsInfarct segment lengthProgressive LV enlargementVALIANT Echo studyLV ejection fractionLeft ventricular enlargementCombination of captoprilACE inhibitor captoprilEnd-diastolic volumeARB valsartanEchocardiographic characteristicsVALIANT studyCardiovascular eventsEchocardiographic parametersLV dysfunctionReceptor blockersLV enlargementVentricular enlargement
2003
Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RM. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both. New England Journal Of Medicine 2003, 349: 1893-1906. PMID: 14610160, DOI: 10.1056/nejmoa032292.Peer-Reviewed Original ResearchConceptsCaptopril groupValsartan groupMyocardial infarctionCardiovascular eventsAdverse eventsHeart failureMost drug-related adverse eventsDrug-related adverse eventsLeft ventricular systolic dysfunctionAngiotensin receptor blocker valsartanAngiotensin converting enzyme (ACE) inhibitorsEnd pointMyocardial Infarction ComplicatedNonfatal cardiovascular eventsDouble-blind trialPrimary end pointVentricular systolic dysfunctionComposite end pointLeft ventricular dysfunctionPopulation of patientsACE inhibitor captoprilAcute myocardial infarctionAdditional therapyCardiovascular morbidityRenal dysfunction